The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience.
Raffaele PesaventoDavide CeccatoGiampaolo PasquettoJacopo MonticelliLucia LeoneAnnachiara FrigoDavide GorgiAnna PostalGiuseppe Maria MarcheseAlberto CiprianiAlois SallerCristiano SaraisPietro CrivellerMarco GemelliFederico CaponePaola FiorettoClaudio PaganoMarco RossatoAngelo AvogaroPaolo SimioniPaolo PrandoniRoberto VettorPublished in: Journal of thrombosis and haemostasis : JTH (2020)
The rate of relevant bleeding events was high in patients treated with (sub)therapeutic doses of anticoagulants. In the latter group, overall mortality did not differ from that of patients treated with standard prophylactic doses and was even higher. Our result does not support a strategy of giving (sub)therapeutic doses of anticoagulants in non-critically ill patients with COVID-19.